NATCO Pharma Limited (BOM:524816)
India · Delayed Price · Currency is INR 793.35
-0.70 (-0.09%)
At close: Oct 28, 2026
NATCO Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 155,561 | 174,489 | 143,064 | 170,522 | 102,795 | 138,013 | |
Market Cap Growth | 5.29% | 21.97% | -16.10% | 65.89% | -25.52% | -8.31% |
Enterprise Value | 141,409 | 145,097 | 124,852 | 160,841 | 93,605 | 133,992 |
Last Close Price | 793.35 | 965.42 | 785.30 | 932.25 | 546.22 | 727.34 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 12.42 | 12.30 | 7.59 | 12.28 | 14.37 | 81.18 |
PS Ratio | 4.46 | 4.28 | 3.23 | 4.26 | 3.80 | 7.09 |
PB Ratio | 1.69 | 1.89 | 1.88 | 2.91 | 2.11 | 3.24 |
P/TBV Ratio | 1.74 | 1.95 | 1.95 | 3.01 | 2.19 | 3.34 |
P/FCF Ratio | 11.27 | 12.64 | 11.04 | 19.55 | 14.63 | - |
P/OCF Ratio | 8.80 | 9.87 | 8.43 | 14.07 | 12.11 | 296.80 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 4.06 | 3.56 | 2.82 | 4.02 | 3.46 | 6.89 |
EV/EBITDA Ratio | 11.78 | 9.96 | 5.82 | 9.19 | 9.68 | 51.54 |
EV/EBIT Ratio | 14.33 | 11.53 | 6.35 | 10.24 | 11.56 | 108.58 |
EV/FCF Ratio | 10.25 | 10.51 | 9.64 | 18.44 | 13.32 | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.08 | 0.08 | 0.04 | 0.07 | 0.04 | 0.10 |
Debt / EBITDA Ratio | 0.67 | 0.49 | 0.13 | 0.22 | 0.18 | 1.64 |
Debt / FCF Ratio | - | 0.52 | 0.22 | 0.44 | 0.25 | - |
Net Debt / Equity Ratio | -0.15 | -0.15 | -0.29 | -0.17 | -0.13 | -0.08 |
Net Debt / EBITDA Ratio | -1.32 | -0.97 | -1.03 | -0.57 | -0.64 | -1.26 |
Net Debt / FCF Ratio | - | -1.02 | -1.71 | -1.15 | -0.88 | 1.76 |
Asset Turnover | - | 0.41 | 0.57 | 0.64 | 0.50 | 0.39 |
Inventory Turnover | - | 0.80 | 0.89 | 0.94 | 0.78 | 0.66 |
Quick Ratio | - | 1.84 | 4.07 | 2.73 | 2.47 | 2.02 |
Current Ratio | - | 3.01 | 5.59 | 4.14 | 4.39 | 3.50 |
Return on Equity (ROE) | - | 16.85% | 27.97% | 25.88% | 15.66% | 4.05% |
Return on Assets (ROA) | - | 7.98% | 15.82% | 15.63% | 9.40% | 1.56% |
Return on Invested Capital (ROIC) | 10.16% | 17.58% | 31.53% | 28.62% | 16.41% | 2.76% |
Return on Capital Employed (ROCE) | - | 13.40% | 25.60% | 26.50% | 16.30% | 2.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 8.05% | 8.13% | 13.18% | 8.14% | 6.96% | 1.23% |
FCF Yield | 8.87% | 7.91% | 9.06% | 5.12% | 6.84% | -1.35% |
Dividend Yield | 0.57% | 0.51% | 0.75% | 1.00% | 0.98% | 0.60% |
Payout Ratio | 7.04% | 6.36% | 5.72% | 12.30% | 14.04% | 48.35% |
Buyback Yield / Dilution | 0.00% | - | 0.21% | 1.67% | -0.08% | 0.04% |
Total Shareholder Return | 0.57% | 0.51% | 0.97% | 2.67% | 0.90% | 0.64% |